Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data

Area of Science:

• Pharmacology
• Oncology
• Immunology

Background:

• The A3 adenosine receptor (A3AR) is overexpressed in various pathological human cells.
• A3AR agonists, piclidenoson and namodenoson, exhibit high affinity and selectivity for A3AR.

Purpose of the Study:

• To evaluate the safety and efficacy of A3AR agonists piclidenoson and namodenoson in preclinical and clinical settings.
• To explore the therapeutic potential of these agents in cancer, inflammatory conditions, and liver diseases.

Main Methods:

• Phase I, II, and III clinical studies were conducted to assess safety and efficacy.
• Molecular mechanisms involving Wnt and NF-κB signaling pathways were investigated.
• Studies included patients with psoriasis, advanced liver cancer, and non-alcoholic steatohepatitis (NASH).

Main Results:

• Piclidenoson demonstrated safety and efficacy in psoriasis patients, improving skin lesions.
• Namodenoson showed prolonged overall survival in advanced liver cancer patients (Child-Pugh B score of 7).
• Namodenoson exhibited anti-inflammatory, anti-fibrosis, and anti-steatosis effects in NASH patients.

Conclusions:

• A3AR agonists are safe and effective drug candidates for various pathological conditions.
• These agents are in advanced clinical development for indications including cancer, psoriasis, and NASH.